Drug intelligence / Profile preview

TERAVID-19

Development stage: Preclinical
Lead developer: ImunoTera
Modality: DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics

Overview

TERAVID-19 is a DNA vaccine candidate developed by the Brazilian biotechnology company ImunoTera for the prevention of COVID-19. The vaccine utilizes a DNA plasmid platform designed to deliver genetic sequences encoding SARS-CoV-2 antigens into host cells. Once inside the cells, these sequences are expressed as viral proteins, which then trigger a robust immune response involving both neutralizing antibodies and T-cell activation. As of early 2024, TERAVID-19 is in the preclinical stage of development, with the goal of providing a stable and effective immunization option against the SARS-CoV-2 virus.

Beyond the preview

Go deeper on TERAVID-19.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TERAVID-19.

Explore the full profile